262 related articles for article (PubMed ID: 10769104)
21. Fracture risk in oral glucocorticoid users: a Bayesian meta-regression leveraging control arms of osteoporosis clinical trials.
Amiche MA; Albaum JM; Tadrous M; Pechlivanoglou P; Lévesque LE; Adachi JD; Cadarette SM
Osteoporos Int; 2016 May; 27(5):1709-18. PubMed ID: 26694595
[TBL] [Abstract][Full Text] [Related]
22. Alfacalcidol versus plain vitamin D in the treatment of glucocorticoid/inflammation-induced osteoporosis.
Ringe JD; Faber H; Fahramand P; Schacht E
J Rheumatol Suppl; 2005 Sep; 76():33-40. PubMed ID: 16142849
[TBL] [Abstract][Full Text] [Related]
23. Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone.
Boutsen Y; Jamart J; Esselinckx W; Devogelaer JP
J Bone Miner Res; 2001 Jan; 16(1):104-12. PubMed ID: 11149473
[TBL] [Abstract][Full Text] [Related]
24. High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study.
Angeli A; Guglielmi G; Dovio A; Capelli G; de Feo D; Giannini S; Giorgino R; Moro L; Giustina A
Bone; 2006 Aug; 39(2):253-9. PubMed ID: 16574519
[TBL] [Abstract][Full Text] [Related]
25. Low bone mineral density, but not epidural steroid injection, is associated with fracture in postmenopausal women with low back pain.
Yi Y; Hwang B; Son H; Cheong I
Pain Physician; 2012; 15(6):441-9. PubMed ID: 23159959
[TBL] [Abstract][Full Text] [Related]
26. Long-term bone loss in kidney transplant recipients: a cross-sectional and longitudinal study.
Pichette V; Bonnardeaux A; Prudhomme L; Gagné M; Cardinal J; Ouimet D
Am J Kidney Dis; 1996 Jul; 28(1):105-14. PubMed ID: 8712204
[TBL] [Abstract][Full Text] [Related]
27. A cost effectiveness analysis of calcium and vitamin D supplementation, etidronate, and alendronate in the prevention of vertebral fractures in women treated with glucocorticoids.
Buckley LM; Hillner BE
J Rheumatol; 2003 Jan; 30(1):132-8. PubMed ID: 12508402
[TBL] [Abstract][Full Text] [Related]
28. Correlation of different bone markers with bone density in patients with rheumatic diseases on glucocorticoid therapy.
Loddenkemper K; Bohl N; Perka C; Burmester GR; Buttgereit F
Rheumatol Int; 2006 Feb; 26(4):331-6. PubMed ID: 15887044
[TBL] [Abstract][Full Text] [Related]
29. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group.
Saag KG; Emkey R; Schnitzer TJ; Brown JP; Hawkins F; Goemaere S; Thamsborg G; Liberman UA; Delmas PD; Malice MP; Czachur M; Daifotis AG
N Engl J Med; 1998 Jul; 339(5):292-9. PubMed ID: 9682041
[TBL] [Abstract][Full Text] [Related]
30. Glucocorticoid-induced osteoporosis: a review on pathophysiology and treatment options.
De Nijs RN
Minerva Med; 2008 Feb; 99(1):23-43. PubMed ID: 18299694
[TBL] [Abstract][Full Text] [Related]
31. Prevention of corticosteroid-induced osteoporosis by alfacalcidol.
Lakatos P; Nagy Z; Kiss L; Horvath C; Takacs I; Foldes J; Speer G; Bossanyi A
Z Rheumatol; 2000; 59 Suppl 1():48-52. PubMed ID: 10769437
[TBL] [Abstract][Full Text] [Related]
32. Influence of recency and duration of glucocorticoid use on bone mineral density and risk of fractures: population-based cohort study.
Majumdar SR; Morin SN; Lix LM; Leslie WD
Osteoporos Int; 2013 Sep; 24(9):2493-8. PubMed ID: 23572142
[TBL] [Abstract][Full Text] [Related]
33. Glucocorticoid-induced osteoporosis: pathogenesis, diagnosis, and management.
McIlwain HH
Prev Med; 2003 Feb; 36(2):243-9. PubMed ID: 12591000
[TBL] [Abstract][Full Text] [Related]
34. Bone mineral density changes in women with systemic lupus erythematosus.
Boyanov M; Robeva R; Popivanov P
Clin Rheumatol; 2003 Oct; 22(4-5):318-23. PubMed ID: 14579164
[TBL] [Abstract][Full Text] [Related]
35. Changes in bone mineral density following discontinuation or continuation of alendronate therapy in glucocorticoid-treated patients: a retrospective, observational study.
Emkey R; Delmas PD; Goemaere S; Liberman UA; Poubelle PE; Daifotis AG; Verbruggen N; Lombardi A; Czachur M
Arthritis Rheum; 2003 Apr; 48(4):1102-8. PubMed ID: 12687554
[TBL] [Abstract][Full Text] [Related]
36. Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy.
Reid DM; Adami S; Devogelaer JP; Chines AA
Calcif Tissue Int; 2001 Oct; 69(4):242-7. PubMed ID: 11730260
[TBL] [Abstract][Full Text] [Related]
37. A multicenter cross sectional study on bone mineral density in rheumatoid arthritis. Italian Study Group on Bone Mass in Rheumatoid Arthritis.
Sinigaglia L; Nervetti A; Mela Q; Bianchi G; Del Puente A; Di Munno O; Frediani B; Cantatore F; Pellerito R; Bartolone S; La Montagna G; Adami S
J Rheumatol; 2000 Nov; 27(11):2582-9. PubMed ID: 11093437
[TBL] [Abstract][Full Text] [Related]
38. Calcium, vitamin D and etidronate for the prevention and treatment of corticosteroid-induced osteoporosis in patients with rheumatic diseases.
Loddenkemper K; Grauer A; Burmester GR; Buttgereit F
Clin Exp Rheumatol; 2003; 21(1):19-26. PubMed ID: 12673885
[TBL] [Abstract][Full Text] [Related]
39. [Basics and management of glucocorticoid-induced osteoporosis].
Willenberg HS; Lehnert H
Internist (Berl); 2008 Oct; 49(10):1186-90, 1192, 1194-6. PubMed ID: 18758741
[TBL] [Abstract][Full Text] [Related]
40. Prolactinomas in adolescents: persistent bone loss after 2 years of prolactin normalization.
Colao A; Di Somma C; Loche S; Di Sarno A; Klain M; Pivonello R; Pietrosante M; Salvatore M; Lombardi G
Clin Endocrinol (Oxf); 2000 Mar; 52(3):319-27. PubMed ID: 10718830
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
